24-Hour blood pressure response to lower dose (30 mg) fimasartan in Korean patients with mild to moderate essential hypertension
Hae-Young Lee, Cheol-Ho Kim, Jae-Kwan Song, Shung Chull Chae, Myung Ho Jeong, Dong-Soo Kim, Byung-Hee Oh
Korean J Intern Med. 2017;32(6):1025-1036. Published online 2017 Oct 17 DOI: https://doi.org/10.3904/kjim.2016.094
Citations to this article as recorded by 
Blood Pressure–lowering Effect of Fimasartan Versus Comparators: A Cross-inference With a Systematic Review and Meta-analysis Through a Quality-management System
Hojin Oh, Kang-Yeon Kim, Duk-Woo Yoo, In Mo Yoon
Clinical Therapeutics.2023; 45(5): 437. CrossRef
A Randomized, Double-blind, Active-controlled, Two Parallel-Group, Optional Titration, Multicenter, Phase IIIb Study to Evaluate the Efficacy and Safety of Fimasartan Versus Perindopril Monotherapy With and Without a Diuretic Combination in Elderly Patien
Hae-Young Lee, Kwang-il Kim, Sang Hyun Ihm, Moo-Yong Rhee, Il Suk Sohn, Sungha Park, Eun-Seok Jeon, Jong-Min Song, Wook Bum Pyun, Ki-Chul Sung, Moo Hyun Kim, Sang-Hyun Kim, Seok-Yeon Kim, Shin-Jae Kim, Eung Ju Kim, Jinho Shin, Sung Yun Lee, Kook-Jin Chun,
Clinical Therapeutics.2021; 43(10): 1746. CrossRef
Long-Term Safety of a Novel Angiotensin Receptor Blocker, Fimasartan, According to the Absence or Presence of Underlying Liver Disease in Korean Hypertensive Patients: A Prospective, 12-Month, Observational Study
Gyu Chul Oh, Kwon Wook Joo, Myung-A Kim, Dong-Ju Choi, Yoon Jun Kim, Hae-Young Lee
Drug Design, Development and Therapy.2020; Volume 14: 1341. CrossRef
Fimasartan: A new armament to fight hypertension
Akshyaya Pradhan, Vikas Gupta, Rishi Sethi
Journal of Family Medicine and Primary Care.2019; 8(7): 2184. CrossRef
PK/PD evaluation of fimasartan for the treatment of hypertension Current evidences and future perspectives
Fabio Angeli, Paolo Verdecchia, Monica Trapasso, Marina Pane, Sara Signorotti, Gianpaolo Reboldi
Expert Opinion on Drug Metabolism & Toxicology.2018; 14(5): 533. CrossRef